ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0797 • ACR Convergence 2021

    Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis

    Michal Doumen1, Diederik De Cock1, Sofia Pazmino1, Delphine Bertrand1, Rene Westhovens2 and Patrick Verschueren3, 1KU Leuven, Leuven, Belgium, 2University Hospitals KU Leuven, Maaseik, Belgium, 3University Hospitals Leuven - KULeuven, Leuven, Belgium

    Background/Purpose: Patient-reported outcomes (PROs) relating to global psychosocial wellbeing are rarely assessed in clinical trials for rheumatoid arthritis (RA), and specifically not to tailor additional…
  • Abstract Number: 0815 • ACR Convergence 2021

    Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID

    DH Solomon1, Theodore Pincus2, Nancy Shadick1, Jacklyn Stratton1, Jack Ellrodt1, Leah Santacroce1, Jeffrey Katz1, Josef Smolen3, Prem Chatpar4, Breanna Mundell4, Mary Stocks4, Christina Downey5, Karina Torralba6, Douglas White7, Meggan Baudek7, Steven Szlembarski7, Sharon Barnhart7, Jawad Bilal8, Dylan Lee8, Albert Redford8, Julia Buchfuhrer9, Helene Kramer8, C. Kent Kwoh10, Michel Villatoro-Villar8, Asha Patnaik11, Edgardo Guzman11, Rebecca Trachtman12, John Tesser13, Dijana Music14, Lexi Mickey15, Mona Amin16, Jeffrey Potter17, Juan Schmukler18, Joshua Sundhar19, Jessica Sheingold20, Diane Horowitz21, Hannah Gulko21, Robert Quinet22, Swathi Dhulipala23, Ronak Patel24, Chandana Keshavamurthy25, Guiset Carvajal Bedoya26, Rhonda Dunn27, Bharat Kumar27, Aleksander Lenert27, Hanna Zembrzuska27 Matthew Gebre28, Petar Lenert29, Allen Anandarjah30, Annie Yang30, Linda Grinnell-Merrick30, Shadefai Goldsmith30, Jonna Zelie30, Leanna Wise31, Nicole Zagelbaum Ward32 and Jeffrey Kaine33 1Brigham and Women's Hospital, Boston, MA, 2Rush University Medical Center, Chicago, IL, 3University of Vienna, Vienna, Austria, 4Dr. Chatpar and Associates, LLC, Plainview, NY, 5Loma Linda University Medical Center, Redlands, CA, 6Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, 7Gundersen Health, La Crosse, WI, 8University of Arizona, Phoenix, AZ, 9University of Arizona, Pheonix, AZ, 10University of Arizona College of Medicine, Tuscon, AZ, 11Stony Brook School of Medicine, Stony Brook, NY, 12Icahn School of Medicine at Mount Sinai, New York, NY, 13Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, 14Arizona Arthritis and Rheumatology Associates, Glendale, AZ, 15Arthritis and Rheumatology Associates- Glendale, Glendale, AZ, 16Arthritis and Rheumatology Associates- Phoenix, Phoenix, AZ, 17Arthritis & Rheumatism Associates, Wheaton, MD, 18Mount Sinai- Chicago, Chicago, IL, 19Arthritis Rheum & Back Disease Assoc., Voorhees, NJ, 20MedStar Georgetown University Hospital, Washington, DC, 21Northwell Health, Great Neck, NY, 22Ochsner Health, River Ridge, LA, 23Ochsner Clinic Foundation, River Ridge, LA, 24Ochsner Health, Jefferson, LA, 25Ochsner, New Orleans, LA, 26University of Colorado, Aurora, CO, 27University of Iowa, Iowa City, IA, 28Loma Linda University Medical Center, Loma Linda, CA, 29University of Iowa Medical School, Iowa City, IA, 30University of Rochester, Rochester, NY, 31LAC+USC/Keck Medicine of USC, Pasadena, CA, 32LAC+USC Medical Center, Los Angeles, CA, 33Cullowhee, NC

    Background/Purpose: TTT has been shown in multiple RCTs to be an effective paradigm for managing RA, however TTT has not been uniformly implemented in US…
  • Abstract Number: 0832 • ACR Convergence 2021

    Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis

    Andrea Rubbert-Roth1, Bernard Combe2, Zoltan Szekanecz3, Stephen Hall4, Boulos Haraoui5, Suzan Mansour Hussein Attar6, Anna-Karin Ekwall7, Yanna Song8, Tim Shaw9, Orsolya Nagy8 and Ricardo Xavier10, 1Kantonspital St Gallen, St.Gallen, Switzerland, 2CHU Montpellier Montpellier University, Montpellier, France, 3Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, 4Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, 5Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 6King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, 7University of Gothenburg, Gothenburg, Sweden, 8AbbVie Inc., North Chicago, IL, 9AbbVie Inc., North Chicago, 10Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) across various patient populations.1–4 This post hoc analysis aimed to evaluate the…
  • Abstract Number: 0958 • ACR Convergence 2021

    Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Christina Charles-Schoeman1, Maya Buch2, Maxime Dougados3, Deepak L Bhatt4, Jon Giles5, Ivana Vranic6, Joseph Wu7, Cunshan Wang7, Sujatha Menon7, Jose L Rivas8, Arne Yndestad9, Carol A Connell7 and Zoltan Szekanecz10, 1Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 2University of Leeds, Leeds, United Kingdom, 3Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, 4Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 5Columbia University, New York, NY, 6Pfizer Inc, Tadworth, Surrey, United Kingdom, 7Pfizer Inc, Groton, CT, 8Pfizer SLU, Madrid, Spain, 9Pfizer Inc, Oslo, Norway, 10Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary

    Background/Purpose: To identify independent risk factors for major adverse cardiovascular (CV) events (MACE) in ORAL Surveillance (NCT02092467), a long-term, randomized, open-label, non-inferiority, Phase 3b/4 safety…
  • Abstract Number: 1017 • ACR Convergence 2021

    Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model

    Maria de la Luz Garcia-Hernandez1, Javier Rangel-Moreno1, Ananta Paine1, Jacob R. Jones1, Marc Nuzzo1, Lidsay N. Schnur2 and Christopher Ritchlin1, 1Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 2University of Rochester, Rochester, NY

    Background/Purpose: Dendritic Cell (DC)-Specific Transmembrane Protein (STAMP) expressed by osteoclast precursors is required for cell-cell fusion in the formation of the osteoclast (OC) polykaryon. Genetic…
  • Abstract Number: 1149 • ACR Convergence 2021

    Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis

    Saffa Iftikhar1, Waleed Khokher2, Ashu Acharya1, Joan Gekonde3, Nithin Kesireddy2, Rawish Fatima1 and Nezam Altorok2, 1University of Toledo Medical Center, Toledo, OH, 2University of Toledo, Toledo, OH, 3University of Toledo, Sylvania Township, OH

    Background/Purpose: Glucocorticoids are commonly used in patients with rheumatologic conditions including but not limited to Rheumatoid Arthritis, Polymyalgia Rheumatica, Systemic Lupus Erythematous and so on.…
  • Abstract Number: 1208 • ACR Convergence 2021

    Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence

    Andrés Ponce1, Beatriz Frade-Sosa2, Ramirez Julio3, Núria Sapena1, Roberto Gumucio2, Virginia Ruiz-Esquide2, Rosa Morlà2, Marta Bassas2, Juan D Cañete4 and Jose A Gomez-Puerta2, 1Rheumatology Department, Hospital Clínic, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital Universitari Clinic, Barcelona, Spain, 4Rheumatology Department, Hospital Clinic, Barcelona, Spain

    Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on the reduction of C reactive protein (CRP) that does not always correlate with a significant improvement…
  • Abstract Number: 1224 • ACR Convergence 2021

    Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab

    Samuel Bitoun1, Bineta Ly2, Signe Hässler3, Audrey Paoletti4, Aude Gleizes5, Salima Hacein-Bey5, Philippe Bröet3, Marc Pallardy6 and Xavier Mariette7, 1Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, 2INSERM U1184, Université Paris Saclay, Le Kremlin Bicêtre, France, 3CESP, INSERM UMR 1018, Universite Paris-Saclay, Villejuif, France, 4INSERM U1184, Université Paris Saclay, le kremlin bicetre, France, 5Hôpital Bicètre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre, France, 6Faculté de Pharmacie, Université Paris-Saclay, Chatenay Mallabry, France, 7Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: Anti-Drug antibodies (ADAb) are well studied and have an impact on response to treatment with monoclonal anti-TNF biologics. Rituximab treatment has an important immunogenic…
  • Abstract Number: 1240 • ACR Convergence 2021

    Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs

    Fang Cai1, Thierry Sornasse2, Feng Hong3, Heidi Camp4, Koji Kato5 and Iain McInnes6, 1AbbVie, Redwood City, CA, 2AbbVie Inc, Redwood City, CA, 3AbbVie, Worcester, MA, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc, Shinagawa- Ku, Japan, 6University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…
  • Abstract Number: 1256 • ACR Convergence 2021

    Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

    Roya Hosseini1, Souhiela fawaz2 and Enrique Seoane-Vazquez2, 1Chapman University School of Pharmacy, Aliso Viejo, CA, 2Chapman University School of Pharmacy, Irvine, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by polyarthritis of small and large joints. RA is the second most common type…
  • Abstract Number: 1523 • ACR Convergence 2021

    Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution

    Megan Hansen, Danny Zakria and Douglas Johnson, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Since the introduction of the first immune checkpoint inhibitor (ICI) in 2011, they have become widely utilized in the treatment of malignancy. It is…
  • Abstract Number: 1655 • ACR Convergence 2021

    Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients

    Lucia Cristina Dominguez Casas1, Paz Rodriguez-Cundin2, Trinidad Dierssen3, Miguel Ángel gonzalez-Gay4 and Ricardo Blanco5, 1Hospital Universtario San Agustin, Oviedo, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3University of Cantabria, Santander, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Marqués de Valdecilla, Santadner, Spain

    Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of severe infections due to the disease itself, and the immunosuppressive treatment. Vaccination programs are designed…
  • Abstract Number: 1671 • ACR Convergence 2021

    COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City

    Jonah Levine1, Vivian Bykerk2, Lindsay Lally1, Lisa Mandl1 and Medha Barbhaiya1, 1Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Hospital for Special Surgery, New York City, NY

    Background/Purpose: COVID-19 in patients with rheumatoid arthritis (RA) is poorly understood. A recent study of mostly men with RA demonstrated increased COVID-19 risk in RA…
  • Abstract Number: 1687 • ACR Convergence 2021

    Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial

    Christina Charles-Schoeman1, Jon Giles2, Nancy Lane3, Ernest Choy4, Dan Furst5, Jiri Vencovsky6, Anthony Wilson7, Gerd Burmester8, Tim Shaw9, Yanna Song10, Heidi Camp10, Nasser Khan10, Jillian Yee10, Samuel Anyanwu10 and Iain McInnes11, 1Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 2Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 3University of California Davis, Hillsborough, CA, 4CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 5University of California Los Angeles, Los Angeles, CA, 6Institute of Rheumatology, Prague, Czech Republic, 7Center for Arthritis Research, Conway Institute, University College Dublin, Dublin, Ireland, 8Charité University Medicine Berlin, Berlin, Germany, 9AbbVie Inc., North Chicago, 10AbbVie Inc., North Chicago, IL, 11University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA). The safety and efficacy of UPA has been…
  • Abstract Number: 1703 • ACR Convergence 2021

    AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis

    Thomas Jonassen1, Thierry Duvauchelle1, Birgitte Telmer2, Irene Sandholdt2, Thomas Boesen1 and Ellen-Margrethe Hauge3, 1SynAct Pharma, Holte, Denmark, 2CroxxMed, Hørsholm, Denmark, 3Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammation and promotion of inflammatory resolution. AP1189 is a biased MC type…
  • « Previous Page
  • 1
  • …
  • 118
  • 119
  • 120
  • 121
  • 122
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology